[250 Pages Report] Newly-released Covid-19 Vaccine Development Tools industry analysis report by Future Market Insights shows that global sales of Covid-19 Vaccine Development Tools in 2021 was held at US$ 17.2 Bn. With 10.7%, the projected market growth during 2022 - 2032 is expected to be significantly higher than the historical growth. Laboratory Technologies are expected to be the highest revenue generating type, accounting for an absolute dollar opportunity of nearly US$ 32.8 Bn during 2022 – 2032.
| Attributes | Details |
|---|---|
| Covid-19 Vaccine Development Tools Market CAGR (2022 to 2032) | 10.7% |
| Covid-19 Vaccine Development Tools Market Size (2022) | US$ 18.9 Billion |
| Covid-19 Vaccine Development Tools Market Size (2032) | US$ 51.6 Billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the Covid-19 Vaccine Development Tools industry research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2020 to 2021, market value of the Covid-19 Vaccine Development Tools industry increased at around 9% CAGR, wherein, countries such as the U.S., UK, China, South Korea and Japan held significant share in the global market.
Owing to this, Covid-19 Vaccine Development Tools market is projected to grow at a CAGR of 10.7% over the coming 10 years.
The industry is expected to maintain its growth in the following years, owing to a large influx of vaccine designers and manufacturers from around the world. Despite the rapid development and deployment of vaccines, the SARS-CoV-2 infection curve has only recently begun to level off, particularly in developed countries.
Several factors are contributing to the development of this market, including artificial intelligence's critical role in the COVID-19 vaccine race, an expanding pool of collaborations to expedite vaccine research and clinical trials, and rigorous funding initiatives by government and private entities. The current environment of expedited vaccine research and clinical trials has motivated collaboration among vaccine developers and industry players.
SARS-COV-2 variants began to appear in the vaccine market in 2020, necessitating recertification of the effectiveness of the first-generation vaccines that were designed for use in that development period.
Pharmaceutical firms are focusing on creating long-term solutions for the SARSCOPE-C disease, which is prompting manufactures such as Thermo Fisher Scientific Inc., Hamilton Company, Sartorius AG, Agilent Technologies, and Bio-Rad Laboratories Inc. to expand their tool portfolio that is used only in the development of the vaccine for COVID-19.
AI has enormous potential to facilitate and revolutionise the discovery of innovative COVID-19 vaccines. AI is expected to play an important role in the development of vaccines for emerging coronavirus variants, and entities operating in this market space are collaborating with vaccine developers to further expand the market. Nanotronics, for example, announced in April 2021 that it has partnered with various key COVID-19 vaccine developers to assist in the efficient management of data linked with COVID-19 vaccine development activities through the use of AI-based online tools.
Principal Consultant
Asia Pacific region is expected to register the highest CAGR during the forecast period due to increased demand for Covid-19 Vaccine Development Tools in developing countries, especially India and China. This can be attributed to its high Covid-affected population.
The International Conference on Genomes, Synaptic RNAs, and Vaccines 2019 hosted more than 420 researchers affiliated with ten international and Chinese institutions, who explored cutting-edge genome sequencing, cells, interactions, and immune response methods. The use of advanced sequencing techniques in China enabled the identification of the COVID-19 genome sequence and allowed the speedy implementation of vaccines against SARS-CoV-2.Chinese researchers used next-generation sequencing, electron microscopy, flow cytometry, and other methods to conduct studies on the SARS-CoV-2 genome, viral structural analysis, and cell imaging.
U.S. accounts for nearly 28% of the global Covid-19 vaccine development tools market revenue. The growth in country’s market can be attributed to a variety of factors, including increased R&D activities, funding initiatives, presence of key players, rising COVID-19 cases, and a high population base receiving COVID-19 vaccine, among others. Furthermore, government initiatives promoting the development of a COVID-19 vaccine can be attributed to market growth. For example, the United States government launched Operation Warp Speed, a public-private collaboration for the development, production, and distribution of COVID-19 vaccines.
Monitoring the rate of mutation is critical for the development of an effective vaccine against SARS-CoV-2. Companies in the United States are developing surveillance infrastructure to track SARS-CoV-2 mutations. Illumina, Inc. and Helix announced their collaboration to build a national surveillance infrastructure in the United States to monitor potential emergence and prevalence of novel SARS-CoV-2 strains in January 2021. Illumina's sequencing technology will be combined with Helix's nationwide testing footprint to expand security efforts established by the federal government for the early detection and evaluation of SARS-CoV-2 variants.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
U.S. accounts for nearly 28% of the global Covid-19 vaccine development tools market revenue. The growth in country’s market can be attributed to a variety of factors, including increased R&D activities, funding initiatives, presence of key players, rising COVID-19 cases, and a high population base receiving COVID-19 vaccine, among others. Furthermore, government initiatives promoting the development of a COVID-19 vaccine can be attributed to market growth. For example, the United States government launched Operation Warp Speed, a public-private collaboration for the development, production, and distribution of COVID-19 vaccines.
Monitoring the rate of mutation is critical for the development of an effective vaccine against SARS-CoV-2. Companies in the United States are developing surveillance infrastructure to track SARS-CoV-2 mutations. Illumina, Inc. and Helix announced their collaboration to build a national surveillance infrastructure in the United States to monitor potential emergence and prevalence of novel SARS-CoV-2 strains in January 2021. Illumina's sequencing technology will be combined with Helix's nationwide testing footprint to expand security efforts established by the federal government for the early detection and evaluation of SARS-CoV-2 variants.
The laboratory technologies segment dominates the market, accounting for over 95% of total revenue. The use of laboratory technologies to grow the potency of vaccines, including polymerase chain reaction, cell culture, hemagglutination, flow cytometry, and spectrometry, is anticipated to favor the growth and delivery of vaccine diagnostic segments over the next five years. PCR and qPCR will constitute the most noteworthy revenue of the laboratory technologies industry in 2020. The broad use of PCR technologies in vaccine surveillance and efficacy testing has led to the industry's rapid expansion.
Medical professionals are also working to bring technologies like vaccine trackers and optimize management systems online. These tools are largely being employed by established companies to conduct research and development activities. Between mid-November 2020 and the present, Vaccine Predictor, a website, has been available online. This tool enables users to evaluate the CDC's recently updated vaccine portfolio and generate development timelines, according to Research and development activities.
Why Vaccine Research Segment Dominates Revenue among Applications?
The vaccine research segment dominated the market, accounting for around 44% of revenue. Several factors, including increased government funding, extensive research by universities and healthcare organisations, and increased business development strategies by prominent pharmaceutical companies, are driving the segment's growth. Furthermore, the segment's growth can be attributed to ongoing research activities aimed at improving the vaccine planning process.
For example, Stanford University researchers are working on developing a single-dose coronavirus vaccine that could potentially be stored at room temperature in January 2021. This could potentially help to reduce the cost of vaccine storage and transportation. Furthermore, for COVID-19 target discoveries, companies are increasingly engaging in business growth strategies such as agreements, alliances, and collaborations.
A new webtool based on the COVID-19 Vaccine Predictor was released in November 2020. This webtool allows users to explore an updated vaccine portfolio and evaluate the timeline for Research and development activities. Scientists collaborated to determine diagnosing and treating infectious diseases during this study to discover useful biomarkers to monitor at-risk individuals. These valuable insights helped to lead to a vaccine against COVID-19.
The key players in Covid-19 vaccine development tools market include Thermo Fisher Scientific, Inc., Celerion, Cole-Parmer Instrument Company, LLC, Pfizer Inc., Sartorius AG, STEMCELL Technologies Inc., AB Sciex Pte. Ltd., Illumina, Inc., Agilent Technologies, and Bio-Rad Laboratories, Inc., among others.
Some of the recent developments of key Covid-19 Vaccine Development Tools providers are as follows:
Similarly, recent developments related to companies offering Covid-19 Vaccine Development Tools have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2032 |
| Historical Data Available for | 2020 to 2021 |
| Market Analysis | US$ Bn for Value |
| Key Regions Covered | North America, Latin America, Europe, Asia-Pacific, and MEA |
| Key Countries Covered | USA, UK, China, Japan, South Korea |
| Key Market Segments Covered | Technology, Application, End-Use |
| Key Companies Profiled |
|
| Pricing | Available upon Request |
The global Covid-19 Vaccine Development Tools market is worth more than US$ 17.2 Bn at present.
Value of Covid-19 Vaccine Development Tools are projected to increase at a CAGR of around 10.7% during 2022 – 2032.
Value of Covid-19 Vaccine Development Tools increased at a CAGR of around 8.9% during 2020 – 2021.
The growing competition amongst the vaccine developers is one of the prominent market drivers for Covid-19 vaccine development tools market.
Top five players of Covid-19 Vaccine Development Tools market include Thermo Fisher Scientific Inc., Celerion, Cole-Parmer Instrument Company Llc., Pfizer, Sartorius AG
Top 5 countries driving demand for Covid-19 Vaccine Development Tools are U.S., U.K., China, Japan, South Korea
Asia Pacific accounted for around 40% of global Covid-19 Vaccine Development Tools demand in 2021.
The European market for Covid-19 Vaccine Development Tools is projected to expand at a CAGR of around 10% during 2022 – 2032.
1. Executive Summary 1.1. Global Market Outlook 1.2. Summary of Statistics 1.3. Key Market Characteristics & Attributes 1.4. FMI Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Risks and Trends Assessment 3.1. Risk Assessment 3.1.1. COVID-19 Crisis and Impact on Covid-19 Vaccine Development Tools 3.1.2. COVID-19 Impact Benchmark with Previous Crisis 3.1.3. Impact on Market Value (US$ Mn) 3.1.4. Assessment by Key Countries 3.1.5. Assessment by Key Market Segments 3.1.6. Action Points and Recommendation for Suppliers 3.2. Key Trends Impacting the Market 3.3. Formulation and Product Development Trends 4. Market Background 4.1. Covid-19 Vaccine Development Tools Market, by Key Countries 4.2. Covid-19 Vaccine Development Tools Market Opportunity Assessment (US$ Mn) 4.2.1. Total Available Market 4.2.2. Serviceable Addressable Market 4.2.3. Serviceable Obtainable Market 4.3. Market Scenario Forecast 4.3.1. Demand in optimistic Scenario 4.3.2. Demand in Likely Scenario 4.3.3. Demand in Conservative Scenario 4.4. Investment Feasibility Analysis 4.4.1. Investment in Established Markets 4.4.1.1. In Short Term 4.4.1.2. In Long Term 4.4.2. Investment in Emerging Markets 4.4.2.1. In Short Term 4.4.2.2. In Long Term 4.5. Forecast Factors - Relevance & Impact 4.5.1. Top Companies Historical Growth 4.5.2. Growth in Automation, By Country 4.5.3. Patch Management Adoption Rate, By Country 4.6. Market Dynamics 4.6.1. Market Driving Factors and Impact Assessment 4.6.2. Prominent Market Challenges and Impact Assessment 4.6.3. Patch Management Market Opportunities 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment 5. Key Success Factors 5.1. Manufacturers’ Focus on Low Penetration High Growth Markets 5.2. Banking on with Segments High Incremental Opportunity 5.3. Peer Benchmarking 6. Global Covid-19 Vaccine Development Tools Market Demand Analysis 2020-2021 and Forecast, 2022-2032 6.1. Historical Market Analysis, 2020-2021 6.2. Current and Future Market Projections, 2022-2032 6.3. Y-o-Y Growth Trend Analysis 7. Global Covid-19 Vaccine Development Tools Market Value Analysis 2020-2021 and Forecast, 2022-2032 7.1. Historical Market Value (US$ Mn) Analysis, 2020-2021 7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Covid-19 Vaccine Development Tools Market Analysis 2020-2021 and Forecast 2022-2032, By Technology 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis By Technology, 2020-2021 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Technology, 2022-2032 8.3.1. Laboratory Technologies 8.3.1.1. Next Generation Sequencing 8.3.1.2. PCR & qPCR 8.3.1.3. Flow Cytometry 8.3.1.4. Spectrometry 8.3.1.5. Microscopy & Electron Microscopy 8.3.1.6. Preparative & Process Chromatography 8.3.1.7. Nucleic Acid Isolation & Purification 8.3.1.8. Transfection Electroporation 8.3.1.9. Cell Culture 8.3.1.10. Automated Liquid Handling 8.3.2. Online Technologies 8.3.2.1. Interactive Web Technologies 8.3.2.2. Vaccine Management & Tracker Technologies 8.4. Market Attractiveness Analysis By Technology 9. Global Covid-19 Vaccine Development Tools Market Analysis 2020-2021 and Forecast 2022-2032, By Application 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis By Application, 2020-2021 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2022-2032 9.3.1. Vaccine Research 9.3.2. Vaccine Process Development 9.3.3. Vaccine Quality Assurance/Quality Control 9.4. Market Attractiveness Analysis By Application 10. Global Covid-19 Vaccine Development Tools Market Analysis 2020-2021 and Forecast 2022-2032, By End-Use 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis By End-Use, 2020-2021 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End-Use, 2022-2032 10.3.1. Pharma & Biopharma Companies 10.3.2. Contract Research Organization (CROs) 10.3.3. Academic & Research Institutes 10.4. Market Attractiveness Analysis By End-Use 11. Global Covid-19 Vaccine Development Tools Market Analysis 2020-2021 and Forecast 2022-2032, By Region 11.1. Introduction 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2020-2021 11.3. Current Market Size (US$ Mn) & Analysis and Forecast By Region, 2022-2032 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. Asia Pacific 11.3.5. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Covid-19 Vaccine Development Tools Market Analysis 2020-2021 and Forecast 2022-2032 12.1. Introduction 12.2. Pricing Analysis 12.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2020-2021 12.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 12.4.1. By Country 12.4.1.1. U.S. 12.4.1.2. Canada 12.4.1.3. Rest of North America 12.4.2. By Technology 12.4.3. By End-Use 12.4.4. By Application 12.5. Market Attractiveness Analysis 12.5.1. By Country 12.5.2. By Technology 12.5.3. By End-Use 12.5.4. By Application 13. Latin America Covid-19 Vaccine Development Tools Market Analysis 2020-2021 and Forecast 2022-2032 13.1. Introduction 13.2. Pricing Analysis 13.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2020-2021 13.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 13.4.1. By Country 13.4.1.1. Brazil 13.4.1.2. Mexico 13.4.1.3. Rest of Latin America 13.4.2. By Technology 13.4.3. By End-Use 13.4.4. By Application 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Technology 13.5.3. By End-Use 13.5.4. By Application 14. Europe Covid-19 Vaccine Development Tools Market Analysis 2020-2021 and Forecast 2022-2032 14.1. Introduction 14.2. Pricing Analysis 14.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2020-2021 14.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 14.4.1. By Country 14.4.1.1. Germany 14.4.1.2. France 14.4.1.3. U.K. 14.4.1.4. Italy 14.4.1.5. Benelux 14.4.1.6. Nordic Countries 14.4.1.7. Rest of Europe 14.4.2. By Technology 14.4.3. By End-Use 14.4.4. By Application 14.5. Market Attractiveness Analysis 14.5.1. By Country 14.5.2. By Technology 14.5.3. By End-Use 14.5.4. By Application 15. Asia Pacific Covid-19 Vaccine Development Tools Market Analysis 2020-2021 and Forecast 2022-2032 15.1. Introduction 15.2. Pricing Analysis 15.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2020-2021 15.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 15.4.1. By Country 15.4.1.1. China 15.4.1.2. Japan 15.4.1.3. South Korea 15.4.1.4. Rest of Asia Pacific 15.4.2. By Technology 15.4.3. By End-Use 15.4.4. By Application 15.5. Market Attractiveness Analysis 15.5.1. By Country 15.5.2. By Technology 15.5.3. By End-Use 15.5.4. By Application 16. Middle East and Africa Covid-19 Vaccine Development Tools Market Analysis 2020-2021 and Forecast 2022-2032 16.1. Introduction 16.2. Pricing Analysis 16.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2020-2021 16.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 16.4.1. By Country 16.4.1.1. GCC Countries 16.4.1.2. South Africa 16.4.1.3. Turkey 16.4.1.4. Rest of Middle East and Africa 16.4.2. By Technology 16.4.3. By End-Use 16.4.4. By Application 16.5. Market Attractiveness Analysis 16.5.1. By Country 16.5.2. By Technology 16.5.3. By End-Use 16.5.4. By Application 17. Key Countries Covid-19 Vaccine Development Tools Market Analysis 2020-2021 and Forecast 2022-2032 17.1. Introduction 17.1.1. Market Value Proportion Analysis, By Key Countries 17.1.2. Global Vs. Country Growth Comparison 17.2. US Covid-19 Vaccine Development Tools Market Analysis 17.2.1. Value Proportion Analysis by Market Taxonomy 17.2.2. Value & Analysis and Forecast by Market Taxonomy, 2020-2032 17.2.2.1. By Technology 17.2.2.2. By End-Use 17.2.2.3. By Application 17.3. Canada Covid-19 Vaccine Development Tools Market Analysis 17.3.1. Value Proportion Analysis by Market Taxonomy 17.3.2. Value & Analysis and Forecast by Market Taxonomy, 2020-2032 17.3.2.1. By Technology 17.3.2.2. By End-Use 17.3.2.3. By Application 17.4. Mexico Covid-19 Vaccine Development Tools Market Analysis 17.4.1. Value Proportion Analysis by Market Taxonomy 17.4.2. Value & Analysis and Forecast by Market Taxonomy, 2020-2032 17.4.2.1. By Technology 17.4.2.2. By End-Use 17.4.2.3. By Application 17.5. Brazil Covid-19 Vaccine Development Tools Market Analysis 17.5.1. Value Proportion Analysis by Market Taxonomy 17.5.2. Value & Analysis and Forecast by Market Taxonomy, 2020-2032 17.5.2.1. By Technology 17.5.2.2. By End-Use 17.5.2.3. By Application 17.6. Germany Covid-19 Vaccine Development Tools Market Analysis 17.6.1. Value Proportion Analysis by Market Taxonomy 17.6.2. Value & Analysis and Forecast by Market Taxonomy, 2020-2032 17.6.2.1. By Technology 17.6.2.2. By End-Use 17.6.2.3. By Application 17.7. France Covid-19 Vaccine Development Tools Market Analysis 17.7.1. Value Proportion Analysis by Market Taxonomy 17.7.2. Value & Analysis and Forecast by Market Taxonomy, 2020-2032 17.7.2.1. By Technology 17.7.2.2. By End-Use 17.7.2.3. By Application 17.8. Italy Covid-19 Vaccine Development Tools Market Analysis 17.8.1. Value Proportion Analysis by Market Taxonomy 17.8.2. Value & Analysis and Forecast by Market Taxonomy, 2020-2032 17.8.2.1. By Technology 17.8.2.2. By End-Use 17.8.2.3. By Application 17.9. BENELUX Covid-19 Vaccine Development Tools Market Analysis 17.9.1. Value Proportion Analysis by Market Taxonomy 17.9.2. Value & Analysis and Forecast by Market Taxonomy, 2020-2032 17.9.2.1. By Technology 17.9.2.2. By End-Use 17.9.2.3. By Application 17.10. UK Covid-19 Vaccine Development Tools Market Analysis 17.10.1. Value Proportion Analysis by Market Taxonomy 17.10.2. Value & Analysis and Forecast by Market Taxonomy, 2020-2032 17.10.2.1. By Technology 17.10.2.2. By End-Use 17.10.2.3. By Application 17.11. Nordic Countries Covid-19 Vaccine Development Tools Market Analysis 17.11.1. Value Proportion Analysis by Market Taxonomy 17.11.2. Value & Analysis and Forecast by Market Taxonomy, 2020-2032 17.11.2.1. By Technology 17.11.2.2. By End-Use 17.11.2.3. By Application 17.12. China Covid-19 Vaccine Development Tools Market Analysis 17.12.1. Value Proportion Analysis by Market Taxonomy 17.12.2. Value & Analysis and Forecast by Market Taxonomy, 2020-2032 17.12.2.1. By Technology 17.12.2.2. By End-Use 17.12.2.3. By Application 17.13. Japan Covid-19 Vaccine Development Tools Market Analysis 17.13.1. Value Proportion Analysis by Market Taxonomy 17.13.2. Value & Analysis and Forecast by Market Taxonomy, 2020-2032 17.13.2.1. By Technology 17.13.2.2. By End-Use 17.13.2.3. By Application 17.14. South Korea Covid-19 Vaccine Development Tools Market Analysis 17.14.1. Value Proportion Analysis by Market Taxonomy 17.14.2. Value & Analysis and Forecast by Market Taxonomy, 2020-2032 17.14.2.1. By Technology 17.14.2.2. By End-Use 17.14.2.3. By Application 17.15. GCC Countries Covid-19 Vaccine Development Tools Market Analysis 17.15.1. Value Proportion Analysis by Market Taxonomy 17.15.2. Value & Analysis and Forecast by Market Taxonomy, 2020-2032 17.15.2.1. By Technology 17.15.2.2. By End-Use 17.15.2.3. By Application 17.16. South Africa Covid-19 Vaccine Development Tools Market Analysis 17.16.1. Value Proportion Analysis by Market Taxonomy 17.16.2. Value & Analysis and Forecast by Market Taxonomy, 2020-2032 17.16.2.1. By Technology 17.16.2.2. By End-Use 17.16.2.3. By Application 17.17. Turkey Covid-19 Vaccine Development Tools Market Analysis 17.17.1. Value Proportion Analysis by Market Taxonomy 17.17.2. Value & Analysis and Forecast by Market Taxonomy, 2020-2032 17.17.2.1. By Technology 17.17.2.2. By End-Use 17.17.2.3. By Application 17.17.3. Competition Landscape and Player Concentration in the Country 18. Market Structure Analysis 18.1. Market Analysis by Tier of Companies 18.2. Market Concentration 18.3. Market Share Analysis of Top Players 18.4. Market Presence Analysis 18.4.1. By Regional footprint of Players 18.4.2. Product footprint by Players 19. Competition Analysis 19.1. Competition Dashboard 19.2. Competition Benchmarking 19.3. Competition Deep Dive 19.3.1. Thermo Fisher Scientific, Inc 19.3.1.1. Overview 19.3.1.2. Product Portfolio 19.3.1.3. Sales Footprint 19.3.1.4. Strategy Overview 19.3.2. Celerion 19.3.2.1. Overview 19.3.2.2. Product Portfolio 19.3.2.3. Sales Footprint 19.3.2.4. Strategy Overview 19.3.3. Cole-Parmer Instrument Company, Llc. 19.3.3.1. Overview 19.3.3.2. Product Portfolio 19.3.3.3. Sales Footprint 19.3.3.4. Strategy Overview 19.3.4. Pfizer 19.3.4.1. Overview 19.3.4.2. Product Portfolio 19.3.4.3. Sales Footprint 19.3.4.4. Strategy Overview 19.3.5. Sartorius AG 19.3.5.1. Overview 19.3.5.2. Product Portfolio 19.3.5.3. Sales Footprint 19.3.5.4. Strategy Overview 19.3.6. Stemcell Technologies Inc. 19.3.6.1. Overview 19.3.6.2. Product Portfolio 19.3.6.3. Sales Footprint 19.3.6.4. Strategy Overview 19.3.7. AB Sciex Pte. Ltd. 19.3.7.1. Overview 19.3.7.2. Product Portfolio 19.3.7.3. Sales Footprint 19.3.7.4. Strategy Overview 19.3.8. Illumina, Inc. 19.3.8.1. Overview 19.3.8.2. Product Portfolio 19.3.8.3. Sales Footprint 19.3.8.4. Strategy Overview 19.3.9. Eurofins Scientific 19.3.9.1. Overview 19.3.9.2. Product Portfolio 19.3.9.3. Sales Footprint 19.3.9.4. Strategy Overview 19.3.10. Agilent Technologies 19.3.10.1. Overview 19.3.10.2. Product Portfolio 19.3.10.3. Sales Footprint 19.3.10.4. Strategy Overview 19.3.11. Bio-Rad Laboratories, Inc. 19.3.11.1. Overview 19.3.11.2. Product Portfolio 19.3.11.3. Sales Footprint 19.3.11.4. Strategy Overview 19.3.12. Danaher 19.3.12.1. Overview 19.3.12.2. Product Portfolio 19.3.12.3. Sales Footprint 19.3.12.4. Strategy Overview 19.3.13. Merck KGaA 19.3.13.1. Overview 19.3.13.2. Product Portfolio 19.3.13.3. Sales Footprint 19.3.13.4. Strategy Overview 19.3.14. Qiagen N.V. 19.3.14.1. Overview 19.3.14.2. Product Portfolio 19.3.14.3. Sales Footprint 19.3.14.4. Strategy Overview 19.3.15. Shimadzu Corporation 19.3.15.1. Overview 19.3.15.2. Product Portfolio 19.3.15.3. Sales Footprint 19.3.15.4. Strategy Overview 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Covid-19 Vaccine Development Tools Market
